Media headlines about Cyberonics (NASDAQ:CYBX) have been trending positive on Wednesday, according to Accern Sentiment. Accern rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cyberonics earned a coverage optimism score of 0.28 on Accern’s scale. Accern also assigned media coverage about the medical device company an impact score of 45.7004063860966 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

ILLEGAL ACTIVITY NOTICE: “Cyberonics (CYBX) Given Daily News Sentiment Score of 0.28” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright and trademark law. The original version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/06/cyberonics-cybx-given-daily-news-sentiment-score-of-0-28.html.

About Cyberonics

Cyberonics, Inc is a medical device company. The Company is engaged in the design, development, sale and marketing of medical devices for epilepsy, depression and heart failure. Its seminal product, the VNS Therapy System, is an implantable device that provides neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression (TRD).

Insider Buying and Selling by Quarter for Cyberonics (NASDAQ:CYBX)

Receive News & Stock Ratings for Cyberonics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyberonics Inc. and related stocks with our FREE daily email newsletter.